A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee

Sengupta K, Alluri KV, Satish AR, et al. · Arthritis Research & Therapy

Both doses significantly improved VAS pain, Lequesne index, and WOMAC scores versus placebo, with the 250 mg dose showing benefit as early as day 7; synovial-fluid MMP-3 fell in treated patients.

Population

Adults with knee osteoarthritis, India

Intervention

5-Loxin (AKBA-enriched Boswellia serrata extract) 100 or 250 mg/day for 90 days

Comparator

Placebo

Limitations

Funded and co-authored by the extract's manufacturer (Laila Nutraceuticals); modest n per arm.